Keio University Hospital

Shinjuku-ku 160-8582

4 studies enrolling now · 12 studies all time

What they study most

Endometrial Cancer, Esophageal Squamous Cell Carcinoma, Ischemic Stroke; Ischemic Attack, Transient, Lupus Erythematosus, Systemic, MAC Lung Disease, Metastatic Cholangiocarcinoma, Metastatic Urothelial Carcinoma, Mycobacterium Infections, Nontuberculous, Pulmonary Arterial Hypertension, Solid Tumor Malignancy, Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR CM), Treatment Refractory MAC Lung Disease

Studies at this site

• A Study of Ifinatamab Deruxtecan in Subjects With Pretreated Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC) (IDeate-Esophageal01) — Recruiting now
• Open-label Extension Study of Seralutinib in Adult Subjects With PAH (PROSERA-EXT) — Recruiting now
• Study of Trastuzumab Deruxtecan Versus Standard of Care Chemotherapy for HER2-Expressing (IHC 3+/2+) Endometrial Cancer — Recruiting now
• A Study of Milvexian in Participants After an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack- LIBREXIA-STROKE — Running, not enrolling
• Efficacy and Safety of Seralutinib in Adult Subjects With PAH (PROSERA) — Completed
• An Extension Study to Assess Long-Term Safety of Eplontersen in Adults With Transthyretin-Mediated Amyloid Cardiomyopathy (ATTR-CM) — Enrolling by invitation
• ICoN-1 Phase 3 Study of the Efficacy and Safety of Treatment With MNKD-101, Clofazimine Inhalation Suspension — Stopped early
• Pemigatinib + Pembrolizumab vs Pemigatinib Alone vs Standard of Care for Urothelial Carcinoma (FIGHT-205) — Stopped early
• Efficacy and Safety of Pemigatinib in Previously Treated Locally Advanced/Metastatic or Surgically Unresectable Solid Tumor Malignancies Harboring Activating FGFR Mutations or Translocations (FIGHT-207) — Stopped early
• A Study to Evaluate the Efficacy and Safety of Pemigatinib Versus Chemotherapy in Unresectable or Metastatic Cholangiocarcinoma — Stopped early
• A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus — Stopped early
• Tezosentan in Patients With Pulmonary Arterial Hypertension — Stopped early